The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
DeFronzo, R. A., Gunnarsson, R., Björkman, O., Olsson, M., & Wahren, J. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111938 · Cited by 1,167
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citation
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationStructural diversity of G protein-coupled receptors and significance for drug discovery
Lagerström, M. C., & Schiöth, H. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2518 · Cited by 1,492
Daneman, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68341-4 · Cited by 921
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Pathogenesis of Type 2 Diabetes Mellitus
Leahy, J. L. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.003 · Cited by 469
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
Self-citationMu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
Self-citationNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Self-citationNauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Self-citationMeier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276
“administration [16, 18, 28].”
Self-citationMa, J., Bellon, M., Wishart, J. M., Young, R., Blackshaw, L. A., Jones, K. L., Horowitz, M., & Rayner, C. K. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90708.2008 · Cited by 254
on behalf of the NN8022-1807 Investigators, Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.149 · Cited by 210
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Self-citationPipatpiboon, N., Pintana, H., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12088 · Cited by 183
“Vildagliptin is a DPP-4 inhibitor that has been shown to increase insulin biogenesis and secretion, improve glycemic control, and reduce HbA1c in both Zucker diabetic fatty rats and clinical studies (Nauck & Meier, 2005; Doupis & Veves, 2008; Jin et al., 2009; Ferreira et al., 2010).”
BackgroundGlucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells
Schlatter, P., Beglinger, C., Drewe, J., & Gutmann, H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2006.12.016 · Cited by 149
Growth factors and beta cell replication
Vasavada, R. C., Gonzalez-Pertusa, J. A., Fujinaka, Y., Fiaschi-Taesch, N., Cozar-Castellano, I., & Garcia-Ocaña, A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.08.003 · Cited by 133
van Zuylen, M. L., Siegelaar, S. E., Plummer, M. P., Deane, A. M., Hermanides, J., & Hulst, A. H. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.01.001 · Cited by 132
Neuroprotective Effects of Liraglutide for Stroke Model of Rats
Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121513 · Cited by 120
“Glucagon-like peptide-1 (GLP-1) analogue is recently established as a daily injection drug for type 2 DM, with actions including stimulation of insulin secretion, glucagon suppression, and appetite loss [1].”
BackgroundResultWang, M.-Y., Yan, H., Shi, Z., Evans, M. R., Yu, X., Lee, Y., Chen, S., Williams, A., Philippe, J., Roth, M. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424934112 · Cited by 112
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Neurotrophic Property of Geniposide for Inducing the Neuronal Differentiation of PC12 Cells
Liu, J., Zheng, X., Yin, F., Hu, Y., Guo, L., Deng, X., Chen, G., Jiajia, J., & Zhang, H. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2006.08.009 · Cited by 86
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
Brakenridge, S. C., Moore, F. A., Mercier, N. R., Cox, M., Wu, Q., Moldawer, L. L., Mohr, A. M., Efron, P. A., & Smith, S. R. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.04.014 · Cited by 46
A model of GLP-1 action on insulin secretion in nondiabetic subjects
Dalla Man, C., Micheletto, F., Sathananthan, A., Rizza, R. A., Vella, A., & Cobelli, C. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00705.2009 · Cited by 45
Nauck, M. A., Kahle, M., Baranov, O., Deacon, C. F., & Holst, J. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12802 · Cited by 44
Self-citationQuast, D. R., Nauck, M. A., Schenker, N., Menge, B. A., Kapitza, C., & Meier, J. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14477 · Cited by 39
Self-citationChen, Y., Zhang, X., He, J., Xie, Y., & Yang, Y. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.12.015 · Cited by 32
Dalla Man, C., Micheletto, F., Sathananthan, M., Vella, A., & Cobelli, C. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0146 · Cited by 24
Metadata
- Authors
- Nauck, M. A., & Meier, J. J.
- Venue
- Regulatory Peptides
- Publisher
- Elsevier BV
- Published
- 2005-06
- Volume
- 128
- Issue
- 2
- Pages
- 135-148
- ISSN
- 0167-0115 (ISSN-L)
- OpenAlex
- W2066406526
- Cited by
- 180
- References
- 33
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.